AmCad BioMed Corp is a Taiwan-based company engaged in the research and development, production and manufacturing of advanced medical devices. The Company's products include AmCAD-UT, an ultrasonic computer-assisted thyroid detection system, AmCAD-US, an acoustic scattering tissue imaging platform, and AmCAD-UT, an ultrasonic Doppler image optimization platform. The Company mainly sells its products domestically and internationally.

Employees

Sector

Advanced Medical Equipment & Technology

More about the company

Quotes

Date	Price	Change	Volume
09/03/26	12.95 NT$	-1.89%	61,735
06/03/26	13.20 NT$	0.00%	57,150
05/03/26	13.20 NT$	0.00%	29,022
04/03/26	13.20 NT$	-4.00%	44,695
03/03/26	13.75 NT$	+1.10%	45,549

End-of-day quote Taipei Exchange

More quotes

Income Statement and Estimates

More financial data

End-of-day quote Taipei Exchange Other stock markets 06/03/2026			5-day change	1st Jan Change
13.20 ^TWD	0.00%		-4.69%	-10.20%

02-26	AmCad BioMed Corporation Reports Earnings Results for the Full Year Ended December 31, 2025	CI
11-11	AmCad BioMed Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI

Capitalization	931M 29.25M 25.22M 22.76M 21.84M 39.83M 2.69B 41.68M 269M 108M 1.29B 110M 107M 4.61B	P/E ratio 2023	-31.4x	P/E ratio 2024	-25.5x
Enterprise value	576M 18.1M 15.61M 14.09M 13.52M 24.65M 1.66B 25.8M 167M 66.72M 798M 67.93M 66.48M 2.85B	EV / Sales 2023	17.6x	EV / Sales 2024	20x
Free-Float	44.78%	Yield 2023 *	-	Yield 2024	-

02-26	AmCad BioMed Corporation Reports Earnings Results for the Full Year Ended December 31, 2025	CI
11-11	AmCad BioMed Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
10/08/25	AmCad BioMed Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
05/05/25	AmCad BioMed Corporation Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
27/02/25	AmCad BioMed Corporation Reports Earnings Results for the Full Year Ended December 31, 2024	CI
13/11/24	AmCad BioMed Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI
31/10/24	AmCad Biomed Corporation to Establish the First Sustainability Development Committee	CI
31/10/24	AmCad BioMed Corporation Announces Change of the Financial Officer	CI
13/08/24	AmCad BioMed Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI
08/08/24	AmCad BioMed Corporation Announces Change of the Financial Officer	CI
08/08/24	AmCad BioMed Corporation Announces Change of the Accounting Officer	CI
08/08/24	AmCad BioMed Corporation Announces Change of the Corporate Governance Officer	CI
07/06/24	AmCad BioMed Corporation announced that it expects to receive TWD 100 million in funding	CI

09/08/22	AmCad BioMed : BOD approve the 2022 second quarter consolidated financial statements	PU
05/07/22	AmCad BioMed : is invited to Online Investor Conference held by KGI Securities	PU
09/06/22	AmCad BioMed : On behalf of our subsidiary Broadsound Co., we announce the major resolutions of 2022 Annual General Shareholders' Meeting.	PU
20/05/22	AmCad BioMed : The major resolutions of 2022 Annual General Shareholders' Meeting.	PU
18/02/22	AmCad BioMed : Announcing termination of private equity offering which was approved by 2021 Annual Shareholders' Meeting.	PU

AmCad BioMed Corporation Stock

Equities

4188

TW0004188008

Advanced Medical Equipment & Technology

Valuation: AmCad BioMed Corporation

Chart: AmCad BioMed Corporation

Latest news: AmCad BioMed Corporation

Press Releases: AmCad BioMed Corporation

Quotes and Performance

Course Extremes

Managers and Directors: AmCad BioMed Corporation

Medical Diagnostic & Testing Equipment

Financials

Company Profile

Quotes

Income Statement and Estimates

1 week	-4.69%
Current month	-4.69%
1 month	-5.04%
3 months	-13.73%
6 months	-18.77%
Current year	-10.20%

1 week	13.1	13.85
1 month	13.1	14.8
Current year	13.1	15.25
1 year	12.3	20
3 years	12.3	37.4
5 years	12.3	37.4
10 years	11.25	43.65

Manager	Title	Age	Since
Yi Li Lee CEO	Chief Executive Officer	55	-
Chih-Yuan Huang DFI	Director of Finance/CFO	-	-
Chun Hsiang Yang CTO	Chief Tech/Sci/R&D Officer	-	11/08/2014

Director	Title	Age	Since
Cheng Chia Li CHM	Chairman	-	06/05/2011
Kuan Chih Chen BRD	Director/Board Member	-	06/05/2011
Yue Ju Lai BRD	Director/Board Member	-	06/05/2011

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
AMCAD BIOMED CORPORATION	0.00%	-4.69%	-34.49%	-20.96%	26.26M
SARTORIUS AG	-1.89%	-9.18%	-6.25%	-47.83%	15.76B
INNER MONGOLIA FURUI MEDICAL SCIENCE CO., LTD.	+2.32%	-13.09%	+70.68%	+71.14%	2.19B
QUIDELORTHO CORPORATION	-5.21%	-13.50%	-49.46%	-77.36%	1.42B
ECKERT & ZIEGLER SE	-1.49%	-1.52%	-17.71%	-23.89%	1.1B
CONTEC MEDICAL SYSTEMS CO.,LTD	+1.69%	-4.30%	+1.19%	-43.05%	843M
SHANGHAI AOHUA PHOTOELECTRICITY ENDOSCOPE CO., LTD.	+0.02%	-8.00%	-1.82%	-43.01%	781M
REVENIO GROUP OYJ	-0.06%	-0.99%	-28.73%	-49.81%	558M
TOMOCUBE, INC.	-0.17%	-9.15%	+297.60%	-	537M
VAREX IMAGING CORPORATION	-6.03%	-17.79%	-13.80%	-39.34%	483M
Average	-1.19%	-5.58%	+21.72%	-30.46%	2.37B
Weighted average by Cap.	-1.88%	-7.86%	+4.32%	-36.76%

	2023	2024
Net sales	65.26M 2.05M 1.77M 1.6M 1.53M 2.79M 188M 2.92M 18.86M 7.56M 90.34M 7.69M 7.53M 323M	53.1M 1.67M 1.44M 1.3M 1.25M 2.27M 153M 2.38M 15.35M 6.15M 73.52M 6.26M 6.13M 263M
Net income	-45.31M -1.42M -1.23M -1.11M -1.06M -1.94M -131M -2.03M -13.1M -5.25M -62.73M -5.34M -5.23M -224M	-50.58M -1.59M -1.37M -1.24M -1.19M -2.16M -146M -2.26M -14.62M -5.86M -70.02M -5.96M -5.84M -250M
Net Debt	-273M -8.57M -7.39M -6.67M -6.4M -11.67M -788M -12.22M -78.87M -31.6M -378M -32.17M -31.49M -1.35B	-355M -11.15M -9.61M -8.68M -8.32M -15.18M -1.02B -15.89M -103M -41.09M -491M -41.83M -40.94M -1.76B